Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...

Merck has launched construction of a $1 billion biologics facility in Wilmington, set to become the U.S. production hub for ...

Microbiotica’s MB097, an oral microbiome-based therapy, shows promise in boosting immunotherapy response in melanoma patients ...

The US FDA has cleared the investigational new drug (IND) application to begin clinical trials for BFB-101, a novel gene ...

Pfizer’s sasanlimab, combined with BCG therapy, significantly improved event-free survival in patients with BCG-naïve, ...

Enhertu (trastuzumab deruxtecan), in combination with pertuzumab, shows promise as a new first-line treatment for ...

The Phase 3 ASCENT-04 clinical trial has demonstrated that combining the antibody-drug conjugate Trodelvy® with the ...

Nimbus Therapeutics announced the launch of a first-in-human clinical trial for NDI-219216, its investigational Werner ...

Biosciences announced the first patient has been dosed in its Phase 2 trial of MB-105, a first-in-class CD5-targeted CAR-T ...

Boehringer Ingelheim has announced a collaboration with Tessellate Bio, to develop a new class of targeted therapies for ...

In the phase 3 HARMONi-6 trial, ivonescimab, Akeso’s PD-1/VEGF bispecific antibody, combined with chemotherapy, demonstrated ...